BOXED O
WARNING O
: O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
EXCERPT O
: O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
( O
A O
) O
Premature O
discontinuation O
of O
XARELTO O
increases O
the O
risk O
of O
thrombotic O
events O
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
increases O
the O
risk O
of O
thrombotic O
events O
. O

To O
reduce O
this O
risk O
, O
consider O
coverage O
with O
another O
anticoagulant O
if O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding O
or O
completion O
of O
a O
course O
of O
therapy O
( O
2.3 O
, O
2.8 O
, O
5.1 O
, O
14.1 O
) O
. O

( O
B O
) O
Spinal/epidural O
hematoma O
Epidural O
or O
spinal O
hematomas O
have O
occurred O
in O
patients O
treated O
with O
XARELTO O
who O
are O
receiving O
neuraxial O
anesthesia O
or O
undergoing O
spinal O
puncture O
. O

These O
hematomas O
may O
result O
in O
long-term O
or O
permanent O
paralysis O
( O
5.2 O
, O
5.3 O
, O
6.2 O
) O
. O

Monitor O
patients O
frequently O
for O
signs O
and O
symptoms O
of O
neurological O
impairment O
and O
if O
observed O
, O
treat O
urgently O
. O

Consider O
the O
benefits O
and O
risks O
before O
neuraxial O
intervention O
in O
patients O
who O
are O
or O
who O
need O
to O
be O
anticoagulated O
( O
5.3 O
) O
. O

A O
. O

Premature O
discontinuation O
of O
XARELTO O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

If O
anticoagulation O
with O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding B-NonOSE_AE
or O
completion O
of O
a O
course O
of O
therapy O
, O
consider O
coverage O
with O
another O
anticoagulant O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
, O
2.8 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

B O
. O
Spinal/epidural O
hematoma O
Epidural B-OSE_Labeled_AE
or O
spinal O
hematomas I-OSE_Labeled_AE
have O
occurred O
in O
patients O
treated O
with O
XARELTO O
who O
are O
receiving O
neuraxial O
anesthesia O
or O
undergoing O
spinal O
puncture O
. O

These O
hematomas B-NonOSE_AE
may O
result O
in O
long-term O
or O
permanent O
paralysis B-NonOSE_AE
. O

Consider O
these O
risks O
when O
scheduling O
patients O
for O
spinal O
procedures O
. O

Factors O
that O
can O
increase O
the O
risk O
of O
developing O
epidural B-NonOSE_AE
or O
spinal O
hematomas I-NonOSE_AE
in O
these O
patients O
include O
: O
* O
use O
of O
indwelling O
epidural O
catheters O
* O
concomitant O
use O
of O
other O
drugs O
that O
affect O
hemostasis O
, O
such O
as O
non-steroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
platelet O
inhibitors O
, O
other O
anticoagulants O
* O
a O
history O
of O
traumatic O
or O
repeated O
epidural O
or O
spinal O
punctures O
* O
a O
history O
of O
spinal O
deformity O
or O
spinal O
surgery O
* O
optimal O
timing O
between O
the O
administration O
of O
XARELTO O
and O
neuraxial O
procedures O
is O
not O
known O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Monitor O
patients O
frequently O
for O
signs O
and O
symptoms O
of O
neurological B-NonOSE_AE
impairment I-NonOSE_AE
. O

If O
neurological B-NonOSE_AE
compromise I-NonOSE_AE
is O
noted O
, O
urgent O
treatment O
is O
necessary O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Consider O
the O
benefits O
and O
risks O
before O
neuraxial O
intervention O
in O
patients O
anticoagulated O
or O
to O
be O
anticoagulated O
for O
thromboprophylaxis B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

